Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Cardiovascular endocrinology

Is ANGPTL3 the next PCSK9?

Nature Reviews Endocrinology volume 13, pages 503–504 (2017)Cite this article

Subjects

Recent reports suggest that molecular therapies targeting ANGPTL3 and its encoded protein angiopoietin-like protein 3 have clinical potential comparable to therapies targeting PCSK9 and its encoded protein proprotein convertase subtilisin/kexin type 9. By mainly affecting triglyceride-rich lipoproteins, ANGPTL3 inhibition might prove complementary to LDL cholesterol lowering with PCSK9 blockade.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Natarajan, P. & Kathiresan, S. PCSK9 inhibitors. Cell 165, 1037 (2016).

    Article  CAS  Google Scholar 

  2. Sabatine, M. S. et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N. Engl. J. Med. 376, 1713–1722 (2017).

    Article  CAS  Google Scholar 

  3. Koishi, R. et al. Angptl3 regulates lipid metabolism in mice. Nat. Genet. 30, 151–157 (2002).

    Article  CAS  Google Scholar 

  4. Romeo, S. et al. Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans. J. Clin. Invest. 119, 70–79 (2009).

    CAS  PubMed  Google Scholar 

  5. Musunuru, K. et al. Exome sequencing. ANGPTL3 mutations, and familial combined hypolipidemia. N. Engl. J. Med. 363, 2220–2227 (2010).

    Article  CAS  Google Scholar 

  6. Teslovich, T. M. et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 466, 707–713 (2010).

    Article  CAS  Google Scholar 

  7. Pashos, E. E. et al. Large, diverse population cohorts of hiPSCs and derived hepatocyte-like cells reveal functional genetic variation at blood lipid-associated loci. Cell Stem Cell 20, 558–570.e10 (2017).

    Article  CAS  Google Scholar 

  8. Dewey, F. E. et al. Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1612790 (2017).

  9. Graham, M. J. et al. Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1701329 (2017).

  10. Stitziel, N. O. et al. ANGPTL3 deficiency and protection against coronary artery disease. J. Am. Coll. Cardiol. 69, 2054–2063 (2017).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Medicine and Genetics, Perelman School of Medicine, University of Pennsylvania, 3400 Civic Center Blvd, 11–104 SCTR, Philadelphia, 19104, Pennsylvania, USA

    Kiran Musunuru

  2. Center for Genomic Medicine, Massachusetts General Hospital, 185 Cambridge Street, CPZN 5.830, Boston, Massachusetts 02114, USA; and at the Program in Medical and Population Genetics, Broad Institute, 75 Ames Street, Cambridge, Massachusetts 02142, USA.,

    Sekar Kathiresan

  3. and at the Program in Medical and Population Genetics, Broad Institute, 75 Ames Street, Cambridge, Massachusetts 02142, USA.,

    Sekar Kathiresan

Authors
  1. Kiran Musunuru
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sekar Kathiresan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sekar Kathiresan.

Ethics declarations

Competing interests

S.K. serves on a scientific advisory board for Regeneron Genetics Center, New York, USA, and has received consulting fees from Ionis Pharmaceuticals, California, USA. K.M. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Musunuru, K., Kathiresan, S. Is ANGPTL3 the next PCSK9?. Nat Rev Endocrinol 13, 503–504 (2017). https://doi.org/10.1038/nrendo.2017.88

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrendo.2017.88

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing